StreetInsider.com News Articles

LB Pharmaceuticals Inc (LBRX) PT Raised to $60 at H.C. Wainwright

Mon, 24 Aug 2026 06:48:56 -0400

(Updated - August 24, 2026 6:48 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on LB Pharmaceuticals Inc (NASDAQ: LBRX) to $60.00 (from $45.00) while maintaining a Buy rating.

The analyst commented: "LB Pharmaceuticals' lead asset, LB-102, is a novel benzamide in late-stage clinical development for psychosis and mood disorders. Top-line data from the Phase 3 NOVA-2 trial of LB-102 in treatment of acute schizophrenia is slated for release in 1H27. The company expects to schedule a pre-NDA meeting with the FDA during 2H27 to finalize the filing requirements for a potential LB-102 submission, which may be completed in

LB Pharmaceuticals Inc (LBRX) PT Raised to $60 at H.C. Wainwright

Mon, 24 Aug 2026 06:48:56 -0400

(Updated - August 24, 2026 6:48 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on LB Pharmaceuticals Inc (NASDAQ: LBRX) to $60.00 (from $45.00) while maintaining a Buy rating.

LB Pharmaceuticals Inc (LBRX) PT Raised to $69 at Clear Street

Thu, 20 Aug 2026 16:18:06 -0400

Clear Street analyst Kaveri Pohlman raised the price target on LB Pharmaceuticals Inc (NASDAQ: LBRX) to $69.00 (from $45.00) while maintaining a Buy rating.

Form SCHEDULE 13G/A LB PHARMACEUTICALS INC Filed by: TCG Crossover GP II, LLC

Fri, 14 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260814/26931217.html

Form SCHEDULE 13G/A LB PHARMACEUTICALS INC Filed by: TCG Crossover GP II, LLC

Fri, 14 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260814/26931217.html

LB Pharmaceuticals Inc (LBRX) PT Raised to $53 at Stifel

Thu, 13 Aug 2026 10:19:48 -0400

(Updated - August 13, 2026 10:19 AM EDT)

Stifel analyst Paul Matteis raised the price target on LB Pharmaceuticals Inc (NASDAQ: LBRX) to $53.00 (from $40.00) while maintaining a Buy rating.

The analyst commented, "We sat down with CEO Heather Turner to discuss the ongoing ph3 study of LB-102 in schizophrenia (data 1H27) and the clinical potential of '102 in other indications. We remain bullish on the prospects of LB-102 following the Vraylar/Caplyta playbook, and we're increasing our target price to reflect additional indication expansion plans in Alzheimer's and schizophrenia negative symptoms. Taking a step back, the thesis here for LB is

LB Pharmaceuticals Inc (LBRX) PT Raised to $53 at Stifel

Thu, 13 Aug 2026 10:19:48 -0400

(Updated - August 13, 2026 10:19 AM EDT)

Stifel analyst Paul Matteis raised the price target on LB Pharmaceuticals Inc (NASDAQ: LBRX) to $53.00 (from $40.00) while maintaining a Buy rating.

Form 4 LB PHARMACEUTICALS INC For: Jul 30 Filed by: Deep Track Biotechnology Master Fund, Ltd.

Wed, 12 Aug 2026 11:03:00 -0400

si-local-file:///var/storage/secattach/20260812/26910863.html

Form 4 LB PHARMACEUTICALS INC For: Jul 30 Filed by: Deep Track Biotechnology Master Fund, Ltd.

Wed, 12 Aug 2026 11:03:00 -0400

si-local-file:///var/storage/secattach/20260812/26910863.html

LB Pharmaceuticals Inc (LBRX) PT Raised to $54 at BMO Capital

Wed, 12 Aug 2026 09:48:02 -0400

BMO Capital analyst Malcolm Hoffman raised the price target on LB Pharmaceuticals Inc (NASDAQ: LBRX) to $54.00 (from $46.00) while maintaining a Outperform rating.

LB Pharmaceuticals Inc (LBRX) Misses Q2 EPS by 93c

Tue, 11 Aug 2026 09:35:33 -0400

LB Pharmaceuticals Inc (NASDAQ: LBRX) reported Q2 EPS of ($1.71), $0.93 worse than the analyst estimate of ($0.78).

For earnings history and earnings-related data on LB Pharmaceuticals Inc (LBRX) click here.

Form 424B3 LB PHARMACEUTICALS INC

Tue, 11 Aug 2026 08:47:00 -0400

si-local-file:///var/storage/secattach/20260811/26902272.html

Form 424B3 LB PHARMACEUTICALS INC

Tue, 11 Aug 2026 08:47:00 -0400

si-local-file:///var/storage/secattach/20260811/26902272.html

Form 10-Q LB PHARMACEUTICALS INC For: Jun 30

Tue, 11 Aug 2026 08:11:00 -0400

si-local-file:///var/storage/secattach/20260811/26901943.html

Form 10-Q LB PHARMACEUTICALS INC For: Jun 30

Tue, 11 Aug 2026 08:11:00 -0400

si-local-file:///var/storage/secattach/20260811/26901943.html

Form 8-K LB PHARMACEUTICALS INC For: Aug 11

Tue, 11 Aug 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26901914.html

Form 8-K LB PHARMACEUTICALS INC For: Aug 11

Tue, 11 Aug 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26901914.html

LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 08:00:00 -0400

Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027

Announced plans for pipeline expansion of LB-102 into new neuropsychiatric indications with strong mechanistic rationale and validating clinical and real-world experience from amisulpride

Cash, cash equivalents, and marketable securities of $327.8 million as of June 30, 2026, and proceeds from recent $150.0 million private placement to fund pipeline expansion, expected to fund operations beyond Q2 2029, through multiple clinical milestones

NEW YORK, Aug. 11, 2026 (GLOBE

LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 08:00:00 -0400

Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027

Announced plans for pipeline expansion of LB-102 into new neuropsychiatric indications with strong mechanistic rationale and validating clinical and real-world experience from amisulpride

NEW YORK, Aug. 11, 2026 (GLOBE

LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 08:00:00 -0400

Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027

Announced plans for pipeline expansion of LB-102 into new neuropsychiatric indications with strong mechanistic rationale and validating clinical and real-world experience from amisulpride

NEW YORK, Aug. 11, 2026 (GLOBE

LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 08:00:00 -0400

Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027

Announced plans for pipeline expansion of LB-102 into new neuropsychiatric indications with strong mechanistic rationale and validating clinical and real-world experience from amisulpride

NEW YORK, Aug. 11, 2026 (GLOBE

Form 4 LB PHARMACEUTICALS INC For: Jul 30 Filed by: Deep Track Biotechnology Master Fund, Ltd.

Mon, 03 Aug 2026 19:28:00 -0400

si-local-file:///var/storage/secattach/20260803/26859795.html

Form 4 LB PHARMACEUTICALS INC For: Jul 30 Filed by: Deep Track Biotechnology Master Fund, Ltd.

Mon, 03 Aug 2026 19:28:00 -0400

si-local-file:///var/storage/secattach/20260803/26859795.html

Piper Sandler on LB Pharmaceuticals Inc (LBRX): 'Competitor Data Highlight LB-102's Blockbuster Value'

Mon, 03 Aug 2026 10:06:00 -0400

Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $78.00 price target on LB Pharmaceuticals Inc (NASDAQ: LBRX).

The analyst commented: "Additional Indications & Competitor Data Highlight LB-102's Blockbuster Value; LBRX continues to demonstrate strong execution with a timely $150M private placement to support LB-102 expansion into additional indications such as schizophrenia negative symptoms and Alzheimer's disease (AD) psychosis/agitation. Accordingly, given LB-102 is a methylated-derivative of amisulpride, we review amisulpride data in schizophrenia negative symptoms and AD where there is clear mechanistic rationale across both. Hence, Additionally, we reviewed topline data from MPLT's (not covered) ML-007C-MA Ph2 ZEPHYR and highlight

Form SCHEDULE 13G/A LB PHARMACEUTICALS INC Filed by: BlackRock, Inc.

Wed, 29 Jul 2026 15:21:00 -0400

si-local-file:///var/storage/secattach/20260729/26834305.html